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ABSTRACT
Background: As congenital cytomegalovirus (CMV)
infection causes signiﬁcant clinical consequences not
only at birth but also later as neurological sequelae, it is
critical to establish a strategy for screening congenitally
infected newborns. Previous studies have identiﬁed an
insufﬁcient sensitivity in screening methods based on
the use of dried blood spots (DBSs).
Objectives: To evaluate the feasibility of the authors’
recently developed method for large-scale screening
for congenital CMV infection and to identify risk factors
for congenital infection.
Methods: More than 21000 newborns were enrolled at
25 sites in six geographically separate areas of Japan.
Urine was collected onto ﬁlter cards placed in the
diapers, which were then analysed by quantitative PCR
using the ﬁlter disc directly as a template. Clinical and
physical ﬁndings of the newborns were extracted from
their medical records. CMV strains from the cases and
their siblings were genetically compared. Viral loads in
DBSs obtained from some of the cases were compared
with those in the urine ﬁlters.
Results: Congenital CMV infection was identiﬁed in
0.31% (95% CI 0.24% to 0.39%) of the newborns, and
30% of the cases (20/66) had typical clinical
manifestations and/or showed abnormalities in brain
images at birth. Although the positive predictive value
of our screening was 94%, the lack of any comparison
with a gold standard assay prevented calculation of the
negative predictive value. Almost two-thirds of the
cases had siblings, a signiﬁcantly higher frequency
than for uninfected newborns. Most of the cases (21/
25) excreted CMV strains identical to those of their
siblings. CMV DNA was undetectable in three out of 12
retrievable DBS specimens.
Conclusions: Implementationofaneffectivelarge-scale
screening programme for congenital CMV infection is
feasible. Siblings are the major risk factor for congenital
CMVinfection,whichemphasisestheneedforeducation
of mothers-to-be as well as vaccine development.
To cite: Koyano S, Inoue N,
Oka A, et al. Screening for
congenital cytomegalovirus
infection using newborn
urine samples collected on
ﬁlter paper: feasibility and
outcomes from a multicentre
study. BMJ Open
2011;1:000118. doi:10.1136/
bmjopen-2011-000118
< Prepublication history and
additional ﬁgures for this
paper are available online. To
view these ﬁles please visit
the journal online (http://
bmjopen.bmj.com).
Received 10 March 2011
Accepted 24 June 2011
This study was presented in
part at the Congenital
Cytomegalovirus Workshop,
22e24 September 2010,
Paris, France.
This ﬁnal article is available
for use under the terms of
the Creative Commons
Attribution Non-Commercial
2.0 Licence; see
http://bmjopen.bmj.com
For numbered afﬁliations see
end of article.
Correspondence to
Dr Naoki Inoue;
ninoue@nih.go.jp
ARTICLE SUMMARY
Article focus
- It is critical to establish a strategy for screening
newborns infected congenitally with cytomega-
lovirus (CMV), as they are at risk for the
development of neurological sequelea. However,
because of the insufﬁcient sensitivity of newborn
CMV screening based on dried blood spots, the
feasibility of an alternative approach using urine
specimens needs to be evaluated.
- Not only population-based epidemiological
studies, but also prospective molecular studies,
are necessary to clarify the transmission routes
of congenital CMV infection.
Key messages
- Collection of urine specimens onto ﬁlter cards
placed in the diapers made large-scale screening
for congenital CMV infection feasible and effec-
tive without compromising detection sensitivity.
- One out of every 300 newborns is congenitally
infected with CMV, and 30% of the cases were
symptomatic in the society where the CMVser-
oprevalence is 70%, indicating that the frequency
of congenital CMV infections is a medical
problem of the same level as Down’s syndrome.
- Our direct molecular evidence indicates that
siblings are the major risk for congenital CMV
infection.
Strengths and limitations of this study
- This multicentre large-scale screening study
demonstrates that our urine-ﬁlter-based method
is robust and reliable. However, the lack of any
comparison with a gold standard assay
prevented the determination of the exact
frequency of false-negative results.
- Serological studies on mothers need to be
combined with newborn screening to conﬁrm
whether transmission predominantly occurs via
maternal primary infection.
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Open Access ResearchINTRODUCTION
Congenital cytomegalovirus (CMV) infection occurs in
0.2e2% of births in developed countries and causes
signiﬁcant clinical consequences not only at birth but
also later as neurological sequelae, including sensori-
neural hearing loss (SNHL) and developmental delay.
1
Our retrospective studies demonstrated that 12e15% of
cases with severe SNHL and 25% of cases with develop-
mental delay of unknown cause were associated with
fetal congenital CMV infection; half of the sequelae were
of late onset.
23Early identiﬁcation of congenital CMV
infection may lead to new treatment options with anti-
viral agents.
4 In addition, early intervention in infants
with SNHL enables language development to reach
a level comparable with that of audiologically normal
peers.
5 As many cases have late-onset SNHL, the ability
of standard newborn hearing screening to detect
congenital CMV-associated SNHL is limited.
6 Therefore,
it is important to establish newborn congenital CMV
screening programmes.
Traditionally, diagnosis of congenital CMV infection
has been performed by the culture of CMV from urine
specimens collected within 3 weeks of birth. As the
collection of liquid urine specimens is laborious, recent
studies have examined the utility of dried blood spots
(DBSs) for congenital CMV diagnosis.
7 8 The arguments
in support of DBS-based assay rely on the presence of
infrastructure for DBS collection and their cost efﬁ-
ciency. However, several studies have found that DBS-
based assays are of limited sensitivity.
91 0Virus loads in
blood, particularly from asymptomatic cases, are very
low,
11 12 which necessitates the use of large DBS discs,
efﬁcient DNA extraction and sensitive PCR assays.
13 14
To overcome the limitations associated with DBS-based
assays, we developed a quantitative PCR (qPCR) assay
using urine specimens collected on ﬁlter discs that can
be used directly as a PCR template without additional
puriﬁcation or elution steps.
11 15
In this study, we established a multicentre congenital
CMV screening programme and tested specimens from
21272 newborns to evaluate the feasibility of our assay
for a relatively large-scale screening programme, to learn
the prevalence of congenital CMV infection and
diseases, and to identify risk factors for congenital CMV
infection in Japan.
METHODS
Study design
The collection and use of human-subject materials was
approved by the Ethical Committee on Human Subjects
of each participating institute. We obtained informed
consent from the parents of all enrolled newborns. The
screening method and study outline are illustrated in
ﬁgure 1. The National Institute for Infectious Diseases
(NIID) in Tokyo distributed ﬁlters with ID numbers to all
study sites. The ID numbers consisted of ﬁve digit
numbers, indicating <area>-<study site within the
area>-<three digits for each newborn ID at the site>.W e
collected urine on a 2 cm35 cm piece of FTA-Elute ﬁlter
cards (Whatman) inserted into the diaper of each
newborn within 4 days of birth and before discharge.
After removal from the diaper, the urine ﬁlter was dried
and mailed to NIID, where it was received within
1e2 days of shipment. The qPCR described in the
following section was performed shortly after receipt of
the specimens (mean of 1.161.2 days). Approximately
70% of distributed ﬁlter cards were recovered for
screening. The main reasons for the non-return of ﬁlters
were (1) that they were used to demonstrate urine
collection techniques to the nurses and paramedicals; (2)
repeated urine collection owing to insufﬁcient urination
prior to diaper change; (3) too much stool on the ﬁlter;
and (4) misplacement of the initial ﬁlter. All ﬁlters were
accounted for as the NIID sent each study site an Excel
ﬁle containing information regarding ﬁlter ID, date of
receipt of the specimens, and test results after each qPCR
run, and each study site added the results to the
newborns’ medical records. There were about 20 occa-
sions on which the study sites emailed or called NIID
because of a typographical error in the ﬁlter ID in the ﬁle.
When the test result was positive, physicians contacted
the parents to arrange an immediate clinic visit for the
collection of urine and blood specimens from the
newborns to conﬁrm congenital CMV infection. Speci-
mens for conﬁrmation were collected at the age of
15.863.8 days (range 7e21 days). Virus isolation, virus
load measurement and serology were performed using
these specimens. In addition to urine specimens, dried
umbilical cord specimens were obtained from 23 of the
cases for further conﬁrmation.
Figure 1 Screening method and study design. ABR, auditory
brainstem responses; CMV, cytomegalovirus; DBS, dried
blood spot; GCV, ganciclovir; VGCV, valganciclovir.
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Screening of Congenital CMV infectionWe obtained separate informed consent to use DBS
specimens from the cases retrospectively for our study,
and requested the incorporated foundations handling
DBSs for sending the specimens. DBS specimens were
retrieved from 12 of the cases, 11 of which were asymp-
tomatic, and one had SNHL at birth. Blood specimens
were obtained from mothers and urine specimens from
siblings.
We established 25 study sites in six geographically
separate areas of Japan. The study sites serve rural,
ruraleurban, and urban/metro societies. More than
99.9% of all babies born at the sites were recruited for
enrolment, and 1.3% of their parents refused participa-
tion. A few infants severely ill in neonatal intensive care
units (NICUs) were excluded owing to difﬁculties in the
collection of urine. Enrolment was carried out from
April 2008 to September 2010. The sites included
primary obstetric clinics and municipal hospitals (type 1
sites), as well as university-associated and national
hospitals (type 2 sites) that care for the general popu-
lation of pregnant women as well as patients referred
from type 1 clinics. Pregnant women are able to select
clinics/hospitals according to their preference. Type 2
sites are generally large in scale, have a NICU and
employ specialists in most clinical areas. Type 1 sites
include Mori Hospital, Tomakomai City Hospital,
Sapporo Tokusyukai Hospital, Nihonmatsu Hospital,
Yamaguchi Hospital, Toyokawa City Hospital, Wakamiya
Hospital, Palmore Hospital, Hanamizuki Ladies Clinic,
Fujita Clinic, Fuchi Ladies Clinic, Miura Clinic for
Women and Children, Miyamura Hospital and Takara
Maternity Clinic. Type 2 sites include National
Fukushima Hospital, National Centre for Child Health
and Development, Iwaki Kyoritsu Hospital, Hyogo
Prefectural Kobe Children’s Hospital and Kariya Toyota
General Hospital, and hospitals at Asahikawa Medical
University, Fukushima Medical University, Tokyo
University, Fujita Health University, Kobe University and
Nagasaki University.
qPCR for screening
We punched a 3 mm diameter disc from the urine ﬁlters,
washed this with 200 ml of water and then transferred it
into 50 ml of qPCR reaction mixture in a well of a 96-well
plate. Only one ﬁlter disc can be submerged into the
reaction mixture after brief centrifugation (400 g, 30 s).
The qPCR assay for the CMV UL84 fragment and
thermal cycling conditions were described previously.
2 15
Although it is ideal to include an internal control to
ensure the absence of PCR inhibition, we did not do so
in this study for the following reasons: (1) although we
initially spiked irrelevant DNA/primers/probe into the
qPCR reaction mixture for screening (n¼200 urine-
ﬁlters) to check the efﬁciency of qPCR, no cases of
inhibition were observed; (2) our previous study
15
demonstrated a close correlation in viral load measure-
ments between the urine-ﬁlter-based qPCR assay and the
common qPCR assay using DNA samples puriﬁed from
liquid urine; and (3) to reduce cost as far as possible. To
conﬁrm positive results in the screening qPCR, DNA
samples were recovered from four 3 mm diameter ﬁlter
discs by incubation at 958C for 30 min in 50 ml of water
containing 100 ng of carrier DNA, and 5 ml aliquots of
the recovered DNA samples were used for qPCR.
15
Simple mathematical consideration of the detection
efﬁciencies (15e20% in qPCR containing urine-ﬁlter vs
60% in qPCR using eluted DNA samples) and the
number of used ﬁlter discs indicates that both qPCR
assays detect almost equivalent amounts of CMV DNA.
The cost for our test itself, including the ﬁlter paper,
reagents, disposables and technical labour for the
assay, was <750 Yen (w£5.50, V7 or US$9) per study
participant.
DNA preparation from specimens other than urine ﬁlters
DNA samples were puriﬁed from liquid urine using
a Viral RNA kit (Qiagen, Hilden, Germany), and from
whole blood using a QIAamp DNAmini kit (Qiagen)
according to the manufacturer’s instructions. DNA was
puriﬁed from dried umbilical cord
2 and DBS
8 specimens
as described previously. The efﬁciency of DNA recovery
from DBS specimens was >90%.
11
Clinical and audiological evaluation
Clinical data for newborns, including birth weight,
gestational age (GA), clinical manifestations and
abnormal laboratory ﬁndings, were extracted from their
medical records. The mental and physical development
of infected infants has been closely monitored at
outpatient clinics. Audiological testing was carried out
using auditory brainstem responses and/or auditory
steady-state responses, and brain imaging was carried out
by CT and/or magnetic resonance images. Although
interpretation of mild abnormalities in brain images
is sometimes difﬁcult, our Study Group contains
a specialist with long experience in paediatric neurology
and brain imaging. Medical records of mothers were
examined for abnormalities during pregnancy. We
deﬁned ‘typical clinical manifestations’ as any of micro-
cephaly, chorioretinitis, SNHL or a combination of
petechiae, hepatosplenomegaly and jaundice. Intra-
uterine growth restriction (IUGR) and any single, mild
manifestation were discounted as ‘typical clinical mani-
festations.’ ‘Symptomatic’ cases were deﬁned as those
exhibiting any typical clinical manifestations and/or
abnormalities in their brain images.
Prior to the initiation of screening, our Study Group
prepared a tentative guideline for antiviral treatment
based on the same protocol and inclusion/exclusion
criteria used in the published clinical trial.
16 Treatment
was performed based on the criteria and informed
consent.
Strain analysis and serology
Sequences of the polymorphic regions of the gN, UL144,
and UL146 genes of CMV strains were determined as
described previously.
17 18 In contrast to European
countries, only 10% of obstetric clinics/hospitals in
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Screening of Congenital CMV infectionJapan conduct routine CMV serology for pregnant
women. In this study, two study sites performed a CMV-
speciﬁc IgG test for all pregnant mothers (n¼4877), and
some sites tested CMV-IgG of pregnant women with any
risk factors (n¼524) at 10e20 weeks of pregnancy. Each
of those sites used one of the following additional tests;
CMV-IgG avidity test for seropositives at 19 weeks of
pregnancy, CMV-IgG test for seronegatives at
35e36 weeks of pregnancy, and CMV-IgG and -IgM tests
for seronegatives during the middle and late terms of
pregnancy. All of their babies except for refusals were
enrolled for CMV screening after birth. Serology tests for
CMV-speciﬁc IgG and IgM were carried out at
a commercial laboratory (SRL, Tokyo, Japan) using EIA
kits produced at DENKA SEIKEN Co. (Niigata, Japan).
The CMV-IgM kit is based on the IgM-captured sandwich
method using CMV-speciﬁc antibodies for detection.
The CMV-IgG avidity test was carried out at Aisenkai
Nichinan Hospital as described previously.
19
Statistical methods
Statistical signiﬁcance was evaluated using the c
2 test.
The ManneWhitney U test was used to analyse differ-
ences in virus loads between two groups. We used
a website (http://www.measuringusability.com/wald.
htm) to calculate adjusted Wald 95% CIs.
RESULTS
Prevalence of congenital CMV infection
Seventy of 21272 newborns were positive in the initial
urine-ﬁlter screening, and all of these were conﬁrmed
positive by the second PCR using DNA samples recovered
from the urine ﬁlters. The positive results were re-exam-
ined with urine specimens collected in liquid form. In two
cases, dried umbilical cord specimens were used for the
conﬁrmation, as there was a delay in urine-ﬁlter collection
owing to accommodation in an NICU in one case and
a delayed clinic visit in the other case. Among the 70 cases
positive in the initial screening, ﬁve urine ﬁlters yielded
9e90 CMV copies/reaction (estimated 3310
4w3310
5
copies/ml urine), which was smaller than those of the
other cases (>200 copies/reaction), and only one of
these ﬁve cases was positive for CMV in the liquid urine
specimens (5.8310
4/ml). CMV was successfully cultured
from all available urine specimens obtained from the
screening-positive cases (n¼50). In addition to the urine
specimens, dried umbilical cord specimens from the cases
(n¼23) were used for further conﬁrmation. In all,
congenital CMV infection was conﬁrmed in a total of 66
newborns (0.31%; 95% CI 0.24 to 0.39%) (table 1). There
were no statistically signiﬁcant differences in the preva-
lence of congenital CMV infection among the six
geographical areas, although life styles ranged from
metropolitan to traditional (data not shown).
Type 2 sites have more patients referred by primary
clinics/hospitals (type 1 sites), and some type 2 sites
enrolled newborns who required NICU care. Thus, there
was a difference between the type 1 and type 2 sites in
the proportion of newborns with a birth weight <2500 g
(5.1% vs 13.5%) but not in that of newborns small for
GA (SGA) (5.1% vs 5.9%). The prevalence of congenital
CMV infections differed approximately twofold between
the two types of study sites (table 1).
Characteristics of CMV-infected newborns
Typical clinical manifestations, deﬁned as any of micro-
cephaly, chorioretinitis, SNHL or a combination of
petechiae, hepatosplenomegaly and jaundice, were
observed in 22.7% (15/66) of the infected newborns
(table 1). SNHL was observed in 53% (8/15) of those
cases. Abnormalities in brain images, including intra-
cranial calciﬁcations, ventricular dilation and abnormal
lesions, were identiﬁed in 10 out of 58 cases. The
proportion of cases with typical clinical manifestations
and/or with the abnormalities in brain images was
30.3% (20/66). As we did not include cases with a single,
mild clinical manifestation and because brain imaging
was not available for eight cases, the proportion of so-
called ‘symptomatic’ cases was likely to have been
underestimated. Cases identiﬁed at type 2 sites had more
frequent clinical manifestations and abnormalities.
Virus loads in whole blood, but not urine, from the
symptomatic cases were statistically higher than those
from asymptomatic cases (supplementary ﬁgure). Virus
loads in the urine were 16- to 22000-fold higher than
those in the blood.
Table 1 Comparison of prevalence and clinical outcomes between types of study sites
All sites
(n[25)
Type 1 sites*
(n[14)
Type 2 sitesy
(n[11)
No of screened newborns 21272 14642 6630
No of congenitally infected cases 66 35 31
Prevalence of congenital infection, % (95% CI) 0.31 (0.24 to 0.40) 0.24 (0.16 to 0.32) 0.47 (0.30 to 0.63)
Abnormalities identiﬁed within 3 months after birth
A: typical clinical manifestations at birth 22.7% (n¼15) 8.6% (n¼3) 38.7% (n¼12)
B: abnormalities in brain images (CT/MRI) 15.2% (n¼10) 11.4% (n¼4) 19.4% (n¼6)
A and/or B 30.3% (n¼20) 17.1% (n¼6) 45.2% (n¼14)
Treated with antiviral drugs 9.1% (n¼6) 0.0% 22.6% (n¼6)
Detectable cytomegalovirus-IgM in blood of the cases 50.8% (30/59) 51.6% (16/31) 50% (14/28)
*Primary obstetric clinics and municipal hospitals.
yUniversity-associated and governmental hospitals that care for general populations as well as patients referred from type 1 clinics.
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Screening of Congenital CMV infectionOf the 66 conﬁrmed cases, six newborns, who
exhibited clinically obvious symptoms, including IUGR,
petechiae, hepatosplenomegaly and jaundice, accompa-
nied by the following abnormalities, SNHL (n¼4),
chorioretinitis (n¼1) and abnormal brain images (n¼3),
were treated with ganciclovir (GCV) and/or valganci-
clovir (VGCV) immediately after diagnosis. In spite of
the intensive treatment, one infant died. In addition,
one child with late-onset SNHL was treated with VGCVat
5 months after birth, and an improvement in SNHL was
observed.
20
Newborns with congenital CMV frequently have siblings
The general characteristics of the newborns enrolled in
this study are summarised in table 2. It is likely that the
uninfected participants represent our average national
population, since the 2009 National Vital Statistics
reported by the Ministry of Health, Labour, and Welfare
in Japan indicates that the average mothers’ age, the
average birth weight and the proportion of newborns
with a birth weight of <2500 g are 31.0 years, 3000 g and
7.7%, respectively, similar to the values observed in our
study population.
Mothers’ age and GA of the infected newborns were
similar to those of the uninfected newborns. However,
the average birth weight of the infected newborns was
slightly less than that of the uninfected newborns. The
differences in the proportion of newborns with a birth
weight of <2500 g and that of SGA were statistically
signiﬁcant, with the differences being more signiﬁcant
in symptomatic cases.
One of the most important ﬁndings of this study is that
infected newborns were more likely to have siblings
(63.6% vs 48.8%, p<0.02). Among the 42 cases with
siblings, 34 had one sibling, seven had two, and one had
three.
Comparison of CMV strains between cases and siblings
We collected urine specimens from the siblings of 34
infected newborns. Twenty-ﬁve of the siblings’ specimens
contained sufﬁcient CMV DNA for PCR ampliﬁcation of
the polymorphic regions of the gN, UL144 and UL146
genes. Eighty-four per cent (21/25) of the pairs had
identical DNA sequences in these genes (table 3). The
mother of one of the four newborns for whom the
sibling strain was not identical is a nurse working in the
department of internal medicine. There was no signiﬁ-
cant linkage of particular genotype(s) with clinical
outcomes. In addition to the 21 pairs, three additional
pairs, symptomatic cases identiﬁed at hospitals outside
the study sites and their siblings, were infected with the
same strains (data not shown).
Technical issues
The ﬁrst issue is the fact that the detection of CMV-
speciﬁc IgM is insensitive for newborn congenital CMV
screening, since CMV-speciﬁc IgM was detectable in
only half (30/59) of the congenital CMV cases (table 1).
The second issue is the choice of specimens for
screening. Viral load estimates obtained from urine-
ﬁlters were in good agreement with those determined
from liquid urine specimens (ﬁgure 2). Viral load esti-
mates from the DBS specimens from the cases (n¼12)
also showed fair agreement with those determined
using blood specimens. Importantly, the total CMV
DNA load in three or four discs of DBS specimens was
far less than that in a single urine-ﬁlter disc, and three
out of 12 DBS specimens were negative in the PCR
assay, the sensitivity of which was previously demon-
strated to be >90%. Finally, adverse events associated
with ﬁlter screening were observed in 0.15% of the
study population. These were mostly minor skin irrita-
tions (ie, redness of skin), but four babies, including
two premature newborns with a body weight <1000 g,
experienced severe perianal skin erosions. Mistakes
such as placing the ﬁlter directly onto the skin rather
than underneath the top layer of the diaper and leaving
the diaper unchanged for an excessive period were the
probable cause.
Table 2 Comparison of general characteristics between the uninfected screened newborns and the identiﬁed congenital
cases
Uninfected
screened newborns Infected cases
p Value
Infected cases with
abnormalities at birthy
n[18330* n[66 n[20
Mean6SD of mothers’ age (years old) 31.264.8 29.765.9 NS 30.665.0
Mean6SD of gestation age 39w1.9d61w2.1d 38w3.9d62w6.1d NS 38w3.7d62w5.2d
Mean6SD of birth weight (g) 3002.96385.2 2756.46463.7 NS 2589.56515.0
Proportion of low birth weight
(<2500 g), % (95% CI)
7.3 (6.9 to 7.7) 22.7 (14.1 to 34.3) <0.001 40 (21.8 to 61.4)
Proportion of those small for gestational
agez, % (95% CI)
5.3 (5.0 to 5.6) 18.2 (10.6 to 29.3) <0.001 30 (14.3 to 52.1)
Proportion of the cases with elder
sibling(s), % (95% CI)
48.8 (48.1 to 49.5) 63.6 (51.6 to 74.2) <0.02 60 (38.6 to 78.2)
*Uninfected newborns whose information was available from 17 study sites in all six areas.
yAbnormalities include typical clinical manifestations and abnormalities found in brain imaging (see the text).
z< 1.5SD in the distribution in the Japanese standard list of birth weight, which is based on sex, number of pregnancy and gestational age.
d, days; w, weeks.
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There were three major outcomes of our study. First, we
demonstrated that the collection of urine specimens in
diapers followed by high-throughput qPCR is feasible for
large-scale screening for congenital CMV. Second, we
provided additional evidence that virus loads in the
blood of symptomatic cases are higher than those in
cases who are asymptomatic at birth
12 21 and that virus
loads in the urine are several orders of magnitude higher
than those in blood,
11 thereby enabling urine-based
screening to detect more congenital CMV cases. Finally,
we found that (1) two-thirds of congenital CMV cases
had siblings, (2) most of the siblings were actively
excreting large amounts of CMV in their urine, and (3)
most of the sibling pairs were excreting identical strains
of CMV. The prevalence of congenital CMV infection,
one out of every 300 newborns, and the presence of
clinical manifestations in 30% of the infected infants
indicate that congenital CMV infection is a serious
medical problem at a level similar to that of Down’s
syndrome, as demonstrated in other studies.
12 2
We found that the urine-ﬁlter collection was not
a burden, either on the newborns or on clinic/hospital
staffs, once they understood the work ﬂow, although it
required extra labour in comparison with DBS-based
screening. Since most babies in Japan are delivered at
clinics/hospitals and stay for 5e6 days, we cannot
predict whether our approach is applicable for babies
delivered at home. However, in one of our studies, we
provided 30 mothers with ﬁlters and an illustration
showing how to collect urine from their 1w2-year-old
children at home, and found that most mothers were
able to send the urine ﬁlters back without any trouble,
suggesting that home collection is possible. The use of
an auto-puncher and a bar-code system may increase the
assay throughput and reliability, although we did not try
this, owing to limited resources.
We should note that one of the limitations of our study
is the lack of any comparison with a gold-standard
screening method, which made it impossible to identify
false-negative cases, although the higher viral loads in
urine are expected to increase the sensitivity of our
Table 3 Comparison of cytomegalovirus strains between cases and their siblings
No
Genotypes of case Sequences between
case and sibling(s)
Genotypes of sibling(s)
gN UL144 UL146 gN UL144 UL146
1 1 A 7 Identical 1 A 7
2 1 A 11 Identical 1 A 11
3 1 B 12 Identical 1 B 12
4 1 C 12 Identical 1 C 12
5 2 A 13 Identical 2 A 13
6 2 B 5 Identical 2 B NA
7 2 B NA Identical 2 NA NA
8 3a A 9 Identical 3a A 9
9 3a A 9 Identical 3a A 9
10 3a C 12 Identical 3a C 12
11 3b C 11 Identical 3b C 11
12 4a A 8 Identical 4a A 8
13 4a A 11 Identical 4a A NA
14 4a A 11 Identical 4a A 11
15 4a B 1 Identical 4a B 1
16 4a C 12 Identical 4a C 12
17 4b A 9 Identical 4b A 9
18 4b B 1 Identical 4b B 1
19 4b B 12 Identical 4b B 12
20 4b C 11 Identical 4b C 11
21 4c B 9 Identical 4c B 9
22 1 B 12 Different 1 A 1
23 2 B 6 Different 3a A 9
24 3a A 1 Different 2 B 12
25 4c A 7 Different 3b B 13
26 2 B 9 Low copy
27 3a B 6 Low copy
28 3a C 12 Low copy
29 3a NA 9 Low copy
30 3a A 7 Low copy
31 3b B 5 Low copy
32 4a A 8 Low copy
33 4c B 11 Low copy
34 NA NA NA Low copy
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Screening of Congenital CMV infectionscreening method. The positive predictive value for
congenital infection in our screening was 94%; in other
words, there were 6% false-positive rates, which empha-
sises the importance of conﬁrmation using additional
materials. We think that this issue is not unique to our
study. The major challenge remaining is how to obtain
additional materials as early as possible, since postnatal
infection via breast milk may interfere with the PCR-
based diagnosis of congenital infection if the materials
are collected after 2 weeks postpartum.
23 Although viral
loads in congenitally infected infants are usually larger
than those in postnatally infected infants, virus isolation
is advised. Fortunately, in Japan we can use dried umbil-
ical cords stored at home for further conﬁrmation.
23A
period (probably 3e5 days) from the collection of urine
ﬁlters to their shipping out can be reduced, since not all
study sites sent the ﬁlters in a timely manner. We do not
have a clear explanation for the causes of the four false-
positive results. At least one of them was collected at the
same site on the same day as a conﬁrmed congenital case,
which suggests the possibility of contamination.
In this study, typical clinical manifestations and/or the
brain image abnormalities were observed in 30% of the
cases. Although the proportion of cases with clinical
manifestations seems to be relatively higher than those
reported previously, some studies have reported ﬁgures
similar to ours.
24 Importantly, the disease deﬁnitions
applied here were similar to those used in most studies.
One of the factors that may have affected the epidemi-
ological outcomes is the selection of study sites. The
prevalence at the type 1 sites may be underestimated,
since mothers with any pregnancy-associated risk factors,
such as IUGR, tend to choose type 2 hospitals that have
an NICU, well-equipped facilities and specialists. In
addition, physicians at type 1 sites prefer to refer those
mothers to type 2 hospitals. Actually, the proportion of
newborns with a birth weight <2500 g at the type 1 sites
was smaller than that at the type 2 sites. In other words,
the prevalence at type 2 sites may have been over-
estimated. Although, ideally, we should know the
proportions of babies born at type 1 and type 2 clinics/
hospitals in our country, such statistics are not available.
Therefore, the true prevalence of CMV infection and
disease in Japan is likely to be somewhere between those
of the type 1 and type 2 sites.
Our ﬁnding that congenital CMV cases were more
likely to have siblings and that case/siblings CMV strains
are often identical is important. Having young children
and recent onset of sexual activities are epidemiologi-
cally major risks for congenital CMV.
22 25 26 A popula-
tion-based study among preadolescents in the USA
demonstrated the importance of family transmission
rather than childcare-centre attendance.
27 However,
demonstration of a relationship between CMV strains
from sources and cases has been limited to comparison
by restriction-enzyme fragment length polymorphism
analysis.
28 29 Since CMV genome sequences are well
conserved, we employed a more robust method based on
the DNA sequences from three polymorphic genes. This
enabled us to demonstrate directly that siblings play
a major role in congenital CMV infections. Related to
this, we have found that 27% (29/108) of 1e5-year-old
healthy children excrete >10000 copies/ml of CMV in
their urine (NI, unpublished data).
An important question is whether maternalefetal
transmission occurs during maternal primary infection,
during reactivation or after reinfection with a different
strain of the virus. A recent meta-analysis demonstrated
that average rates of primary and recurrent infections
were 32% and 1.4%, respectively.
24 Strain-speciﬁc
serology showed that two-thirds of congenital CMV
infections in seropositive women in Alabama were
caused by reinfection,
30 and that reinfections with
different strains are common in healthy women in the
USA and Brazil.
31 32 CMV seroprevalence in Japan is
estimated to be 71.2%, ranging geographically from 69%
to 76%,
33 which is lower than those in Alabama and
Brazil, and similar to those (40e80%) in European
countries.
34 A limitation of this study is that serological
data were available only for 15 of the 66 mothers of the
congenital cases, since CMV serology during pregnancy
is not common practice in Japan. Among the 15
mothers, ﬁve seroconverted during their pregnancies,
ﬁve had CMV-speciﬁc IgM (at least three of them had
a low CMV-IgG avidity index) during their pregnancies,
and ﬁve were already seropositive at the early stage of
pregnancy. Based on our preliminary strain-speciﬁc
serology, it is unlikely that reinfection is the major route
of infection in Japan (Ikuta, Suzutani, et al unpublished).
Figure 2 Comparison of viral loads in 1 ml of whole blood or
urine that were estimated based on dried-blood-spot- (DBS)- or
urine-ﬁlter-based PCR assay (x-axis) with those that were
measured by qPCR using a liquid form of blood or urine
specimens (y-axis). Closed and open circles indicate the
comparison between DBS-based estimates and
measurements of the whole-blood specimens and between
urine-ﬁlter-based estimates and measurements of urine
specimens, respectively. The detection limit of the assays
(indicated with broken lines) was 200 copies/ml.
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Screening of Congenital CMV infectionThus, we think that at least half of the congenital CMV
infections we identiﬁed most likely occurred during
maternal primary infection.
Our study suggests that young children in a family are
the major risk factor for transmission to their pregnant
mothers. A signiﬁcant proportion of pregnant mothers
may be constantly exposed to CMV at home since, as
described above, at least a quarter of young children
excrete 0.5e1 l of urine containing >10000 copies/ml
of CMV daily, often for >2 years. Because of this, devel-
opment of a vaccine to prevent CMV must become
a national and international priority. A recent clinical
trial using gB subunit vaccine provided a promising
direction.
35 In the mean time, serological screening
coupled with educational counselling of seronegative
mothers-to-be can decrease seroconversion.
36 37
Our study clearly demonstrates the feasibility of
implementing large-scale and effective screening
programmes that will enable strategies for timely clinical
intervention and treatment that minimise the damage
caused by congenital CMV-associated sequelae.
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